Want to join the conversation?
$GILD said it is stopping its combined Phase 2/3 clinical study of GS-5745 in patients with moderate to severe ulcerative colitis, or ulcers in the colon. The decision was taken after an interim analysis by the Data Monitoring Committee recommended that the study be terminated early due to meeting pre-specified futility and efficacy criteria.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.